The Molecular Biology of Furin-Like Proprotein Convertases in Vascular Remodelling

Methods in Molecular Biology

Volumn 768, Issue , 2011, Pages 191-206

  Stawowy, Philipp ^a   Kappert, Kai ^b  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

atherosclerosis; furin; laser capture microdissection; proprotein convertases; Vascular smooth muscle cells

Indexed keywords

FURIN; INTEGRIN; MATRIX METALLOPROTEINASE; PROPROTEIN CONVERTASE 5; PROTEIN PRECURSOR; SERINE PROTEINASE INHIBITOR;

ANIMAL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; MALE; METABOLISM; METHODOLOGY; MICRODISSECTION; RAT; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FURIN; HUMANS; INTEGRINS; MALE; MATRIX METALLOPROTEINASES; MICRODISSECTION; MUSCLE, SMOOTH, VASCULAR; PLAQUE, ATHEROSCLEROTIC; PROPROTEIN CONVERTASE 5; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; SERINE PROTEINASE INHIBITORS;

ANIMALIA;

EID: 80054739248     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-204-5_9     Document Type: Chapter

References (21)

1. Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., and Capewell, S. (2007) Explaining the decrease in US deaths from coronary disease, 1980–2000 N Engl J Med 356, 2388–98.
2. Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S., Ho, M., Howard, V., Kissela, B., Kittner, S., Lackland, D., Lisa-beth, L., Marelli, A., McDermott, M., Meigs, J., Mozaffarian, D., Nichol, G., O‘Donnell, C., Roger, V., Rosamond, W., Sacco, R., Sorlie, P., Stafford, R., Steinberger, J., Thom, T., Wasserthiel-Smoller, S., Wong, N., Wylie-Rosett, J., and Hong, Y. (2009) Heart disease and stroke statistics—2009 update: A report from the American heart association statistics committee and stroke statistics subcommittee Circulation 119, e21–181.
3. Libby, P., and Theroux, P. (2005) Pathophysiology of coronary artery disease Circulation 111, 3481–8.
4. Leblond, J., Laprise, M. H., Gaudreau, S., Grondin, F., Kisiel, W., and Dubois, C. M. (2006) The serpin proteinase inhibitor 8: An endogenous furin inhibitor released from human platelets Thromb Haemost 95, 243–52.
5. Stawowy, P., Blaschke, F., Kilimnik, A., Goetze, S., Kallisch, H., Chretien, M., Marcinkiewicz, M., Fleck, E., and Graf, K. (2002) Proprotein convertase PC5 regulation by PDGF-BB involves PI3-kinase/p70(s6)-kinase activation in vascular smooth muscle cells Hypertension 39, 399–404.
6. Stawowy, P., Meyborg, H., Stibenz, D., Borges Pereira Stawowy, N., Roser, M., Thanabalasingam, U., Veinot, J. P., Chretien, M., Seidah, N. G., Fleck, E., and Graf, K. (2005) Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis Circulation 111, 2820–7.
7. Varshavsky, A., Kessler, O., Abramovitch, S., Kigel, B., Zaffryar, S., Akiri, G., and Neufeld, G. (2008) Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like proprotein convertases Cancer Res 68, 6922–31.
8. Stawowy, P., Kallisch, H., Borges Pereira Stawowy, N., Stibenz, D., Veinot, J. P., Grafe, M., Seidah, N. G., Chretien, M., Fleck, E., and Graf, K. (2005) Immunohistochemical localization of subtilisin/kexin-like proprotein convertases in human atherosclerosis Virchows Arch 446, 351–9.
9. Chretien, M., Seidah, N. G., Basak, A., and Mbikay, M. (2008) Proprotein convertases as therapeutic targets Expert Opin Ther Targets 12, 1289–300.
10. Doran, A. C., Meller, N., and McNamara, C. A. (2008) Role of smooth muscle cells in the initiation and early progression of atherosclerosis Arterioscler Thromb Vasc Biol 28, 812–19.
11. Dzau, V. J., Braun-Dullaeus, R. C., and Sedding, D. G. (2002) Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies Nat Med 8, 1249–56.
12. Stawowy, P., Graf, K., Goetze, S., Roser, M., Chretien, M., Seidah, N. G., Fleck, E., and Marcinkiewicz, M. (2003) Coordinated regulation and colocalization of alphav integrin and its activating enzyme proprotein convertase PC5 in vivo Histochem Cell Biol 119, 239–45.
13. Stawowy, P., Kallisch, H., Veinot, J. P., Kilimnik, A., Prichett, W., Goetze, S., Seidah, N. G., Chretien, M., Fleck, E., and Graf, K. (2004) Endoproteolytic activation of alpha(v) integrin by proprotein convertase PC5 is required for vascular smooth muscle cell adhesion to vitronectin and integrin-dependent signaling Circulation 109, 770–6.
14. Stawowy, P., and Fleck, E. (2005) Proprotein convertases furin and PC5: Targeting atherosclerosis and restenosis at multiple levels J Mol Med 83, 865–75.
15. Kappert, K., Furundzija, V., Fritzsche, J., Margeta, C., Kruger, J., Meyborg, H., Fleck, E., and Stawowy, P. (2010) Integrin cleavage regulates bidirectional signalling in vascular smooth muscle cells Thromb Haemost 103, 556–63.
16. Kappert, K., Meyborg, H., Baumann, B., Furundzija, V., Kaufmann, J., Graf, K., Stibenz, D., Fleck, E., and Stawowy, P. (2009) Integrin cleavage facilitates cell surface-associated proteolysis required for vascular smooth muscle cell invasion Int J Biochem Cell Biol 41, 1511–17.
17. Clowes, A. W., Reidy, M. A., and Clowes, M. M. (1983) Mechanisms of stenosis after arterial injury Lab Invest 49, 208–15.
18. Tulis, D. A. (2007) Rat carotid artery balloon injury model Methods Mol Med 139, 1–30.
19. Graeme, I. M., and Curran, S. (2005) Laser Capture Microdissection: Methods and Protocols. Clifton, NJ: Humana Press. 319 pp.
20. Schefe, J. H., Lehmann, K. E., Buschmann, I. R., Unger, T., and Funke-Kaiser, H. (2006) Quantitative real-time RT-PCR data analysis: Current concepts and the novel “gene expression’s CT difference” formula J Mol Med 84, 901–10.
21. Kappert, K., Paulsson, J., Sparwel, J., Leppanen, O., Hellberg, C., Ostman, A., and Micke, P. (2007) Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation FASEB J 21, 523–34.